Kenji Kitatani's Colleagues at InnoCan Pharma
Kenji Kitatani's Contact Details
Hawaii,United States
InnoCan Pharma
Kenji Kitatani's Company Details
InnoCan Pharma is a pharmaceutical company specializing in developing novel therapeutics that harness the unique healing properties of Cannabinoids to improve quality of life. OUR ADVANTAGES Led by a highly-experienced team with a proven track record of success, InnoCan will leverage Israel's worldleading medical cannabis research community to develop powerful, Cannabinoid-combined, patent-pending formulas. Our outstanding products will be clinically validated by undertaking Post Marketing Surveillance (PMS) studies and combine smart delivery systems to enhance the potency and efficacy of current products for better results. EXPECTED EARLY REVENUES: InnoCan expects to generate early revenues ($30 million in 5 years) from the multi-billion dollar Over The Counter (OTC) market by leveraging the rapid FDA OTC drug monograph process or similar regulatory pathways in Europe and Canada. These regulatory pathways enable InnoCan, in a very short time, to bring to market outstanding new products that combine the huge therapeutic potential of Cannabinoid complex/hemp oil added "excipients" to existing approved OTC drugs.TECHNOLOGY: POWERFUL, PATENT PENDING FORMULAS WITH SMART DELIVERY SYSTEMS InnoCan's products will be highly differentiated within the market through the powerful synergistic effect of the Cannabis-complex Hemp Oil with the active ingredients, combined with our on-demand release delivery system providing improved patient efficacy and compliance. FIRST-LINE PRODUCTS: A LEAP-FORWARD IN DERMATOLOGY TREATMENT DESIGNThe companies first products will initially target the multi-billion dollars markets of psoriasis and localized pain , where research shows topical cannabinoid-combined treatments are highly effective, followed by oral hygiene, eczema/ itching, skin support after chemotherapy and women's health. To join the investment opportunity with InnoCan, please contact Iris Bincovich at IrisB@InnocanPharma.com.